Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Must have completed the double-blind portion of the preceding trial

• Completed any protocol specified withdrawal phase and follow-up visits.

Exclusion Criteria:

• Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.